Listing 1.18 in 2026: How Social Security Decides Major Joint Disorder SSDI Claims for Hip, Knee, Shoulder, Ankle, and Wrist Under Paragraph A Chronic Joint Pain or Stiffness, Paragraph B Abnormal Motion or Instability, Paragraph C Anatomical Abnormality on Examination or Imaging, and Paragraph D Functional Limitation With Walker, Bilateral Cane, Crutch, or Wheelchair Documentation

By Anthony Albert, Benefits Research Director, Disability Exchange · Updated June 28, 2026 · SSA Blue Book Section 1.00 Musculoskeletal Disorders (Adult)

Major joint disorders are some of the most common physical bases for an SSDI claim and one of the most misunderstood listings in the Blue Book. Severe knee osteoarthritis, end-stage hip OA, failed total knee or hip replacement, rotator cuff destruction, severe rheumatoid arthritis attacking a major joint, post-traumatic ankle arthritis, and chronic shoulder instability all run through Listing 1.18. The April 2021 musculoskeletal revision rewrote 1.18 with a clean four-paragraph structure that is much tighter than the old Listing 1.02 it replaced. SSA wants the file to prove every paragraph, and the proof has to land inside a four-month window that the Section 1.00C7c proximity rule tightly defines.

This guide walks the 1.18 path in full. We cover the verbatim regulatory text, the 1.00I definitions of "major joint" for upper and lower extremities, the 1.00C2 physical examination documentation rule, the 1.00C6 assistive device documentation rule, the 1.00C6a "documented medical need" definition, the 1.00C7c four-month proximity window, and the 1.00E3 functional criteria. We end with two worked Massachusetts and Florida cases showing how a real file is built.

If you are filing a major joint SSDI claim, the goal is a file that shows A, B, C, and D simultaneously or within close proximity of time. See If You Qualify.

Listing 1.18 Verbatim

All four paragraphs are connected with AND, not OR. You have to clear every one. The harshest gate in real-world claims is Paragraph D and the assistive device requirement.

1.00I: What Counts as a Major Joint

SSA defines major joints in Section 1.00I. The list is short and specific:

• Major joint of an upper extremity. The shoulder, elbow, and wrist-hand. SSA treats the wrist and hand together as one major joint.
• Major joint of a lower extremity. The hip, knee, and ankle-foot. SSA treats the ankle and hindfoot together as one major joint.

The toes, fingers, and small spine facet joints are NOT major joints for 1.18 purposes. Spine claims go through Listing 1.15 (nerve root compromise) or 1.16 (cauda equina or lumbar spinal stenosis). Small-joint rheumatoid arthritis without a major joint involved runs through Listing 14.09 inflammatory arthritis.

SSA also defines what counts as an "anatomical abnormality" and a "functional abnormality" under 1.00I. An anatomical abnormality is one readily observable during a physical exam (subluxation, contracture) or present on imaging (joint space narrowing, bony destruction, ankylosis, deformity). A functional abnormality is abnormal motion or instability of the affected joint, including limitation of motion, hypermobility, lateral deviation, or fixation. Paragraph C wants the anatomical piece. Paragraph B wants the functional piece. They are not the same thing.

Paragraph A: Chronic Joint Pain or Stiffness

Paragraph A is the easiest paragraph to satisfy but the easiest to get sloppy about. SSA wants chronic, not acute. Chronic means a documented history of pain or stiffness across multiple visits over months, not a single ER report. The file should include:

• Primary care notes mentioning pain at the affected joint across at least three to six office visits, with documented severity (numeric pain scale 0-10 or visual analog scale).
• Orthopedist or rheumatologist notes confirming chronicity.
• Medication record showing escalation from over-the-counter analgesics to prescription NSAIDs, neuropathic pain agents, or opioids.
• PT or OT notes describing functional limitations tied to the joint.

Stiffness can substitute for pain. Patients with ankylosing spondylitis, advanced rheumatoid arthritis, or severe post-traumatic joint contracture often have more stiffness than pain. The chart language matters. "Decreased range of motion with end-range stiffness" reads well at DDS. "Range of motion is full" does not.

Paragraph B: Abnormal Motion, Instability, or Immobility

Paragraph B is where the physical exam carries weight. SSA wants the medical source to document one of three things:

• Abnormal motion. Reduced range of motion measured in degrees using a goniometer, lateral deviation, hypermobility outside the normal plane, or trick movements that compensate for the abnormality.
• Instability. Documented giving-way of the joint, positive Lachman or anterior drawer for ACL, positive McMurray for meniscal, positive Trendelenburg gait for hip abductor weakness, positive apprehension test for shoulder instability, varus or valgus laxity on stress testing.
• Immobility. Fibrous or bony ankylosis, surgical arthrodesis, or contracture severe enough to fix the joint in a non-functional position.

SSA refers back to 1.00C2 for what makes a physical exam report acceptable. The medical source has to detail the orthopedic findings from direct observation. SSA will not accept a report that just restates the patient's symptoms. The treating physician's range of motion measurements at the actual visit, not the patient's self-report, are what the examiner reads. Under 1.00C2c, when reduced muscle strength is in the picture, the report must use a recognized grading system. SSA cites the 0 to 5 scale: 0 (no contraction), 1 (trace), 2 (poor, active ROM with gravity eliminated), 3 (fair, active ROM against gravity but no resistance), 4 (good, active ROM against gravity with moderate resistance), 5 (normal). If hand involvement is in the picture, grip and pinch strength have to be measured.

Paragraph C: Anatomical Abnormality on Exam or Imaging

Paragraph C is the imaging or physical exam anatomy paragraph. SSA gives the examiner two roads:

1.18C1: Anatomical Abnormality on Physical Examination

Subluxation, contracture, or bony or fibrous ankylosis observed during the exam counts. The medical source needs to document the finding with anatomical specificity. "Right knee fixed in 25 degrees of flexion contracture, inability to achieve full extension" reads cleanly. "Right knee deformity" does not.

1.18C2: Anatomical Abnormality on Imaging

This is where most claims live. The imaging report has to show one of the listed findings. Joint space narrowing, bony destruction, or ankylosis or arthrodesis are the examples in the rule. SSA does not require Kellgren-Lawrence grading by name, but most orthopedic radiology reports use it for OA:

For RA and inflammatory arthritis cases, bony erosion on plain film or MRI evidence of synovitis with cartilage destruction satisfies the anatomy requirement. For avascular necrosis (AVN of hip or knee), the Ficat-Arlet staging (I to IV) is the radiology standard. Ficat-Arlet stages III and IV satisfy 1.18C2. For post-arthroplasty cases, periprosthetic radiolucency, component loosening on weight-bearing X-ray, or imaging-confirmed periprosthetic joint infection (PJI) all satisfy 1.18C2. Weight-bearing X-rays are critical for knee and hip OA cases. Non-weight-bearing films routinely understate severity by a full K-L grade.

Paragraph D: The 12-Month Functional Limitation Plus Assistive Device Gate

Paragraph D is the gate that kills most underbuilt 1.18 claims. SSA requires impairment-related physical limitation of musculoskeletal functioning that has lasted or is expected to last 12 months PLUS one of three specific functional documentations. There is no fourth option.

1.18D1: Bilateral Hand-Held or Two-Hand Wheeled Device for Lower Extremity Limits

This is the path most knee and hip OA claims take. SSA requires documented medical need for one of:

• A walker (rolling, two-wheeled, four-wheeled, or rollator with seat)
• Bilateral canes (two canes, not one)
• Bilateral crutches (axillary or forearm)
• A wheeled and seated mobility device involving the use of both hands (most manual wheelchairs)

A single cane is not enough under 1.18D1. SSA explicitly designed the listing to exclude single-cane users from listing-level severity. A claimant who walks with a single cane goes to Step 5 RFC analysis, not Step 3.

1.18D2: One Upper Extremity Out Plus One-Handed Lower Extremity Device

This path is rare but important. It covers claimants whose major joint disorder takes one upper extremity out of work AND whose lower extremity disorder requires a one-handed cane or one-handed wheeled mobility device. Example: severe shoulder destruction in the right arm plus advanced knee OA requiring a left-handed cane. The right arm fails 1.00E4 fine and gross movement testing, and the left arm is committed to the cane, leaving no work-capable upper extremity.

1.18D3: Both Upper Extremities Out

For bilateral upper extremity major joint disorders such as severe bilateral rotator cuff destruction, bilateral RA with shoulder and wrist-hand involvement, or bilateral elbow ankylosis. The claimant cannot use either upper extremity for fine and gross movements as defined at 1.00E4.

1.00C6: What "Documented Medical Need" Means for an Assistive Device

This is the documentation rule most claimants miss. SSA defines "documented medical need" at 1.00C6a as evidence from a medical source supporting your medical need for an assistive device for a continuous period of at least 12 months. The evidence must describe any limitations in your upper or lower extremity functioning AND the circumstances for which you need to use the device. SSA does NOT require a specific prescription for the device. A clinic note saying "patient ambulates with bilateral canes, needed for stability due to advanced bilateral knee OA, expected to be permanent" satisfies the rule.

The 12-month window is the critical phrase. The evidence has to support that the device will be needed for 12 continuous months, not just that you happen to be using one this month. Post-surgical use of crutches for six weeks after total knee replacement does not satisfy 1.18D unless the surgical complication (loosening, PJI, fracture, dislocation) makes the device permanent.

SSA also recognizes that some claimants use different devices for different settings. A manual wheelchair for community ambulation plus a walker indoors counts under 1.18D1. PT, OT, and physiatry notes documenting both settings carry more weight than a single primary-care chart entry.

1.00C7c: The Four-Month Proximity Rule

For 1.18 (and several other musculoskeletal listings), all of the required criteria must appear in the medical record within a consecutive 4-month period. SSA also recognizes a 12-month window for claims determined or decided during the pandemic period or post-pandemic evaluation period, but the standard 4-month window applies to most 2026 decisions. Once that severity level is established, the medical record must also show that the level of severity has continued or is expected to continue for at least 12 months.

The four-month window is a trap for the unwary. If your pain documentation is from January 2024, your imaging is from July 2024, your physical exam findings are from December 2024, and your assistive device documentation starts in March 2025, no four-month window contains all four. The DDS examiner reads that as failure to prove simultaneous severity. The fix is to time the records around a single hub visit. Ask the orthopedist to document Paragraph A pain, Paragraph B exam findings, Paragraph C imaging review, and Paragraph D assistive device need in the same visit note. Imaging within four months of that visit satisfies the imaging anchor. Pre-existing assistive device use that the source confirms is ongoing satisfies Paragraph D.

The 2025-2026 Surgical and Treatment Picture

Modern treatment of major joint disorders is aggressive, and SSA reads the treatment record as evidence of severity. The 2025 AAOS Annual Meeting and the 2024 American Joint Replacement Registry reported:

• Over 1.05 million primary total knee arthroplasties (TKA) annually in the US through 2025.
• About 620,000 primary total hip arthroplasties (THA) annually.
• About 90,000 to 100,000 revision arthroplasties annually combined.
• Periprosthetic joint infection (PJI) rate at 1 to 2 percent for primary procedures and 5 to 10 percent for revisions.
• Robotic-assisted arthroplasty (Mako, ROSA, NAVIO, CORI) used in roughly 40 percent of primary TKA cases in 2025, up from 12 percent in 2020.
• Outpatient TKA and THA grew to roughly 30 percent of total volume in 2025 driven by CMS payment policy changes from 2018 and 2020.

The treatment record SSA wants to see for advanced OA cases typically includes a stepwise progression:

1. Activity modification, weight loss counseling, and OTC analgesics (acetaminophen, topical NSAIDs).
2. Prescription NSAIDs (meloxicam, celecoxib, diclofenac).
3. Intra-articular corticosteroid injections (triamcinolone, methylprednisolone).
4. Viscosupplementation hyaluronic acid injections (Synvisc, Euflexxa, Orthovisc, Supartz, Monovisc, Durolane). 2026 CMS policy continues to cover knee HA injections every six months despite mixed efficacy literature.
5. Platelet-rich plasma (PRP) and biologics (not Medicare-covered as of 2026, but in many private orthopedic chart records).
6. Genicular nerve blocks and radiofrequency ablation for knee OA pain.
7. Joint preservation surgery (high tibial osteotomy, hip arthroscopy for FAI).
8. Total joint arthroplasty (primary TKA, THA, total shoulder, reverse total shoulder for cuff arthropathy, total ankle replacement).
9. Revision arthroplasty for complications.
10. Resection arthroplasty or arthrodesis (last-resort salvage).

For inflammatory arthritis (RA, PsA, AS) attacking a major joint, the 2025 ACR guidelines push aggressive treatment with conventional DMARDs (methotrexate, leflunomide, sulfasalazine) plus biologic DMARDs as needed. The biologic classes in active 2026 use:

• TNF inhibitors. Adalimumab (Humira, plus seven approved biosimilars now in market through 2025), etanercept (Enbrel), infliximab (Remicade, biosimilars Inflectra, Renflexis, Avsola, Ixifi), certolizumab pegol (Cimzia), golimumab (Simponi, Simponi Aria).
• T-cell co-stimulation blocker. Abatacept (Orencia).
• B-cell depletion. Rituximab (Rituxan, biosimilars Riabni, Ruxience, Truxima).
• IL-6 inhibitors. Tocilizumab (Actemra), sarilumab (Kevzara).
• IL-17 inhibitors for PsA and AS. Secukinumab (Cosentyx), ixekizumab (Taltz), bimekizumab (Bimzelx) approved 2023.
• IL-23 inhibitors for PsA. Guselkumab (Tremfya), risankizumab (Skyrizi).
• IL-12/23 inhibitor. Ustekinumab (Stelara, multiple biosimilars approved 2024-2025).
• JAK inhibitors. Tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq).

A claim file documenting failure of two or more biologic DMARDs from different classes is severity proof. SSA examiners trained on inflammatory arthritis recognize that pattern as treatment-refractory disease.

Post-Arthroplasty Complications That Build a 1.18 File

Some of the strongest 1.18 cases come from arthroplasty patients with complications. The replacement worked initially, then a complication produced ongoing disability. Common complications and how they read in the file:

• Periprosthetic joint infection (PJI). Often requires two-stage revision with antibiotic spacer for six to twelve weeks, then second-stage reimplantation. The spacer period locks the joint and produces severe functional limitation. PJI patients often need bilateral assistance for prolonged periods. Documentation: serial CRP and ESR, joint aspiration cultures, MSIS criteria for PJI diagnosis, ID consultations.
• Periprosthetic fracture. Vancouver classification (B1, B2, B3 for hip; Lewis-Rorabeck classification for knee). Surgical fixation or revision required, often with prolonged non-weight-bearing.
• Dislocation of THA. Recurrent dislocations require revision with constrained liner or dual mobility cup. Three or more dislocations in 12 months is severity evidence.
• Aseptic loosening. Component migration on serial radiographs. Pain with weight-bearing. Revision indicated.
• Polyethylene wear and osteolysis. Long-term complication of older designs; revision with bone grafting often required.
• Failed total ankle arthroplasty (TAA). Higher failure rate than knee or hip. Salvage with tibiotalocalcaneal arthrodesis often produces a permanent functional disability.
• Stiffness post-TKA requiring manipulation under anesthesia (MUA) or arthroscopic lysis of adhesions. Persistent flexion contracture above 10 degrees or flexion limited below 90 degrees produces real functional limit.

Step 5 RFC Erosion When 1.18D Falls Short

The most common reason 1.18 fails is the assistive device gap. The claimant has Paragraph A, B, and C cleanly but uses only a single cane or no device at all. SSR 96-9p erosion of the sedentary occupational base is the Step 5 pathway. The vocational expert at hearing should be cross-examined on:

• Standing and walking limits. Sedentary work allows up to two hours of standing or walking in an eight-hour day. Limits of one hour or less erode the sedentary base.
• Sit-stand option. A required at-will sit-stand option, especially if combined with the need to raise the leg to chair height or higher, eliminates most sedentary jobs.
• Reaching limits. For shoulder claims, occasional or less than occasional overhead reaching takes a substantial fraction of sedentary jobs off the table.
• Manipulative limits. For wrist-hand claims, less than frequent fingering or handling eliminates most unskilled sedentary work.
• Absences and off-task time. Two unscheduled absences per month or off-task time above 10 percent generally eliminates competitive employment.

The applicable Grid Rules at sedentary RFC are 201.06 (advanced age 55+ with limited education and unskilled work history, direct), 201.10 (50-54 closely approaching advanced age with limited education and unskilled work history, direct), and 201.14 (50-54 with high school graduate and no transferable skills, direct). Most 1.18 RFC wins happen at the closely-approaching-advanced-age threshold of 50.

The Medical Source Statement Counterweight

The orthopedist or rheumatologist medical source statement is the highest-value document in a 1.18 file. It should include:

• Diagnosis with ICD-10 code and date of onset.
• Affected joint or joints, with anatomical specificity.
• Most recent imaging findings with K-L grade or Ficat-Arlet stage.
• Range of motion measurements in degrees.
• Muscle strength using the 0 to 5 grading system, with grip and pinch strength if hand involved.
• Treatment history including conservative care, injections, surgical procedures, and complications.
• Current medications with dosages.
• Assistive device need with specific 1.00C6a language: "medical need for [device] for at least 12 continuous months."
• Functional limitations in standing, walking, sitting, lifting, carrying, fingering, handling, reaching, and postural activities.
• Estimate of off-task time, absences per month, and any need to raise the affected limb.

Under 20 CFR 404.1520c, supportability and consistency are the top persuasiveness factors. A medical source statement that cross-references each limit to a specific exam finding or imaging result wins on both.

Worked Example: Brian 57 Worcester MA Bilateral Knee OA

Worked Example: Maria 53 Tampa FL Failed Total Hip Arthroplasty

How to Build a Winning 1.18 File

1. Time the records to a four-month window. Paragraphs A, B, C, and D all have to be in the medical record within a consecutive 4-month period under 1.00C7c. Schedule the hub visit. Imaging within the four months. Assistive device documentation either spanning the window or with confirmed ongoing use.
2. Get weight-bearing X-rays. Non-weight-bearing knee and hip films routinely understate severity by a K-L grade. Standing AP and lateral are the standard.
3. Document the assistive device with 1.00C6a language. The treating source should say "documented medical need for [walker/bilateral canes/bilateral crutches/manual wheelchair] for at least 12 continuous months." Avoid soft language like "patient uses a cane sometimes."
4. Get the medical source statement keyed to 1.18A-D. Each paragraph addressed by name, with specific exam findings and imaging cited.
5. Build the treatment history. NSAIDs, injections, viscosupplementation, surgical history, complications. Every step is severity evidence.
6. For inflammatory arthritis, document biologic DMARD failures. Two or more biologics across different classes is severity proof.
7. For post-arthroplasty cases, document the complication trail. PJI, dislocation, fracture, loosening, MUA. Every complication adds severity weight.
8. Plan the Step 5 fallback. If 1.18D fails on assistive device gap, get the orthopedist MSS to address standing, walking, sitting, sit-stand option, lift, carry, finger, handle, reach, and absences.

Where Each Joint Type Fits Within Section 1 and Beyond

1.18 is the main path for hip, knee, shoulder, ankle, and wrist-hand cases. For spine claims, see Listing 1.15 cervical and lumbar nerve root compromise. For amputation cases, see Listing 1.20 amputation. For peripheral neuropathy paired with joint disease, see Listing 11.14 peripheral neuropathy. For chronic pain syndromes overlapping joint disease, the related CRPS coverage applies. For inflammatory arthritis with extra-articular manifestations attacking lungs, eyes, or skin, Listing 14.09 inflammatory arthritis may be a better fit. State-specific filing guides for MA, FL, CA, TX, NY, and PA are at Massachusetts, Florida, California, Texas, New York, and Pennsylvania.

Frequently Asked Questions